Navigation Links
GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
Date:6/22/2011

GAITHERSBURG, Md., June 22, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced that Adel A.F. Mahmoud, M.D., Ph.D. and Edward M. Connor, Jr., M.D. were elected to the Company's Board of Directors at its annual meeting of stockholders held on June 15, 2011.  

"Drs. Mahmoud and Connor bring a wealth of experience, especially in infectious disease and vaccine development, to GenVec.  As we expand the breadth and scope of our vaccine programs there is no substitute for the knowledge that comes from the successful introduction of new products into the marketplace," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

Adel A.F. Mahmoud, M.D., Ph.D., 69, is a Professor at Princeton University in the Department of Molecular Biology and the Woodrow Wilson School of Public and International Affairs a position he has held since 2007. In 2006, he retired as the Chief Medical Advisor, Vaccines and Infectious Diseases and a member of the Management Committee of Merck & Co., Inc., a pharmaceutical company, following a six year tenure as President of Merck Vaccines. During that period, Dr. Mahmoud led the effort to launch four new vaccines against rotavirus, human papillomavirus, shingles and a combination of Measles, Mumps, Rubella and Varicella. Dr. Mahmoud currently serves as a director of Becton, Dickinson and Company and Sanaria, Inc. He also serves on numerous scientific advisory boards and is the chairman of the National Institutes of Health's Blue Ribbon Panel to Advise on the Risk Assessment of the National Emerging Infectious Diseases Laboratories at Boston University Medical Center and the National Academy of Sciences' Committee on the Prevention of Proliferation of Biological Weapons.

Edward M. Connor, Jr., M.D., 59, is the Director, Office of Innovation Development and Investigational Therapeutics at Children's National Medical Center and a Professor of Pediatrics, Microbiology, Immunology and Tropical Medicine at George Washington University School of Medicine and Health Sciences, positions he has held since 2008. From 2004 to 2008, Dr. Connor was the Chief Medical Officer and Executive Vice President of MedImmune, Inc., where he had previously served as a Senior Vice President, Clinical Development from 2000 to 2004, Vice President, Clinical Development from 1995 to 2000, and Director, Clinical Studies from 1994 to 1995. He currently serves as the Chief Medical Officer for 3-V Biosciences, a biopharmaceutical company for the treatment of infectious diseases, a position he has held since 2010. Dr. Connor has also served on numerous advisory boards and is the Children's National Representative on the VP-Pharma Board of Directors.

At the annual meeting held on June 15, 2011, stockholders also re-elected two incumbent directors, Kevin M. Rooney and Marc R. Schneebaum, to continue to serve on the Board.  In April 2011, the Board voted to increase its size by one member.  Leaving the Board is Joshua Ruch who did not stand for re-election.  The Board now has 8 members.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, manufacturing, the development of products, and the success of the collaboration with Novartis, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; uncertainties related to the outcome and process of GenVec's previously announced strategic review, dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.Retail Investor and Media Contact: GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

dswirsky@genvec.com

Institutional Investor Contact:S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

susan@sanoonan.com
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
2. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Reports Third Quarter 2010 Financial Results
5. GenVec Forms Collaboration With World-Leading Animal Health Company
6. GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
7. GenVec to Host First Quarter 2011 Earnings Call and Webcast
8. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
9. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
10. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
11. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 Information products ... metrics in Scopus , the world,s largest abstract ... access to comprehensive metrics for journals from over 5,000 publishers. The ... which journals to subscribe to and when to adjust a journal,s ... , , ...
(Date:12/8/2016)... ALBANY, New York , December 8, 2016 ... the global Diabetes Injection Pens Market is expected ... as compared to US$4.9 bn in 2015. Between the forecast ... to rise at a CAGR of 7.9%. The leading players ... Nordisk A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health ... . , Results of the comparative usability study demonstrate that a dictation-based method ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for ... In Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues ... implant and prosthetic market in the U.S. is projected to reach $6.4 billion in ...
(Date:12/8/2016)... ... , ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced ... program, at their world headquarters of Omni La Costa Resort & Spa in San ... seeking weight loss, personal development, a healthy lifestyle, or mental and physical healing. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
Breaking Medicine News(10 mins):